Applying toxicological risk assessment principles to constituents of smokeless tobacco products: Implications for product regulation

Tobacco Control

Volumn 20, Issue 1, 2011, Pages 53-57

  Ayo Yusuf, Olalekan A ^a,b   Connolly, Greg N ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADMIUM; NICOTINE; NITROSAMINE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; CHEWING GUM; HUMAN; METHODOLOGY; NEOPLASM; RISK ASSESSMENT; SMOKELESS TOBACCO; STANDARD; UNITED STATES;

CADMIUM; CHEWING GUM; HUMANS; NEOPLASMS; NICOTINE; NITROSAMINES; REFERENCE STANDARDS; RISK ASSESSMENT; TOBACCO, SMOKELESS; UNITED STATES;

EID: 78650629130     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tc.2010.037135     Document Type: Article

References (40)

1. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-675.
2. Keen P. Trace elements in plants and soil in relation to cancer. S Afr Med J 1974;48:2363-2364.
3. Feng BJ, Khyatti M, Ben-Ayoub W, et al. Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 2009;101:1207-1212.
4. International Agency for Research on Cancer. Smokeless tobacco and some tobacco-specific N-nitrosamines. In: IARC Monographs on the evaluation of Carcinogenic Risks to Humans, Volume 89. Lyon, IARC Press, 2007.
5. Sasco AJ, Merrill RM, Dari I, et al. A case-control study of lung cancer in Casablanca, Morocco. Cancer Causes Control 2002;13:609-616.
6. Simen-Kapeu A, La Ruche G, Kataja V, et al. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Côted'Ivoire and Finland) with different tobacco exposure. Cancer Causes Control 2009;20:63-70.
7. Report on Carcinogens, 11th Edition; U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program. http://ntp.niehs.nih.gov/ntp/roc/eleventh/profiles/s176toba.pdf (accessed 11 Dec 2009).
8. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol 1998;28:1-16.
9. Prignot JJ, Sasco AJ, Poulet E, et al. Alternative forms of tobacco use. Int J Tuberc Lung Dis 2008;12:718-727.
10. Fowles J, Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control 2003;12:424-430.
11. Vorhees DJ, Dodson RE. Estimating risk to cigarette smokers from smoke constituents in proposed "Testing and Reporting of Constituents of Cigarette Smoke" Regulations. Boston (MA): Menzie-Cura & Associates, Inc, 1999.
12. Pankow JF, Watanabe KH, Toccalino PL, et al. Calculated cancer risks for conventional and "potentially reduced exposure product" cigarettes. Cancer Epidemiol Biomarkers Prev 2007;16:584-592.
13. Burns DM, Dybing E, Gray N, et al. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob Control 2008;17:132-141.
14. Rickert WS, Joza PJ, Trivedi AH, et al. Chemical and toxicological characterization of commercial smokeless tobacco products available on the Canadian market. Regul Toxicol Pharmacol 2009;53:121-133.
15. Swedish Match Company. Gothiatek standards. Swedish Match Company. http://www.swedishmatch.com/en/Snus-and-health/Our-quality-standard-GothiaTek/GothiaTek-standards (accessed on 11 Dec 2009).
16. Carcinogenic Potency Database (CPDB). Berkeley: University of California. http://potency.berkeley.edu/pdfs/ChemicalTable.pdf (accessed on 11 Dec 2009).
17. Andersson G, Bjornberg G, Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: A comparative study. J Oral Path Med 1994;23:161-167.
18. Digard H, Errington G, Richter A, et al. Patterns and behaviors of snus consumption in Sweden. Nicotine Tob Res 2009;11:1175-1181.
19. US Food and Drug Administration notice (1983) Action levels for total volatile N-Nitrosamines in rubber baby bottle nipples; availability of compliance policy guide. Fed. Reg., 48, 57014-57017.
20. Nicorette. http://www.nicorette.com/Quit_Place_Dose.aspx (accessed 17 Oct 2009).
21. Raw M, McNeill A, West R. Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority. Thorax 1998;53(Suppl 5 Pt 1):S1-S19.
22. Järup L, Berglund M, Elinder CG, et al. Health effects of cadmium exposure -a review of the literature and a risk estimate. Scand J Work Environ Health 1998;24:1-51.
23. Toxicological profile for lead. 2007. http://www.atsdr.cdc.gov/toxprofiles/tp13.pdf (accessed on 13 Dec 2009).
24. Stepanov I, Upadhyaya P, Carmella SG, et al. Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev 2008;17:1764-1773.
25. Nisbet IC, LaGoy PK. Toxic equivalency factors (TEFs) for polycyclic aromatic hydrocarbons (PAHs). Regul Toxicol Pharmacol 1992;16:290-300.
26. Stepanov I, Villalta PW, Knezevich A, et al. Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry. Chem Res Toxicol 2010;23:66-73.
27. Ramesh A, Walker SA, Hood DB, et al. Bioavailability and risk assessment of orally ingested polycyclic aromatic hydrocarbons. Int J Toxicol 2004;23:301-333.
28. McNeill A, Bedi R, Islam S, et al. Levels of toxins in oral tobacco products in the UK. Tob Control 2006;15:64-67.
29. Lugon-Moulin NM, Zang F, Gadani L, et al. Critical review of science and options for reducing cadmium in tobacco (nicotiana tabacum L.) and other plants. Adv Agron 2004;83:111-180.
30. Schwartz GG, Reis IM. Is cadmium a cause of human pancreatic cancer? Cancer Epidemiol Biomarkers Prev 2000;9:139-145.
31. Ragan HA, Mast T. Cadmium inhalation and male reproductive toxicity. Rev Environ Contam Toxicol 1990;114:1-22.
32. Agency for Toxic Substances and Disease Registry. Draft Toxicological Profile for Cadmium. Atlanta, GA: Agency for Toxic Substances and Disease Registry, 2008.
33. Stepanov I, Jensen J, Hatsukami D, et al. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob Res 2008;10:1773-1782.
34. Stepanov I, Carmella SG, Briggs A, et al. Presence of the carcinogenic N'-Nitrosonornicotine in the urine of some users of oral nicotine replacement therapy products. Cancer Res 2009;69:8236-8240.
35. WHO Study group on tobacco product regulation. Report on setting regulatory limits for carcinogens in smokeless tobacco. Report on the scientific basis of tobacco product regulation: third report of a WHO study group. WHO technical report series no. 955. Geneva: WHO publications, 2009:23-38.
36. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology 2003;8:419-431.
37. Nair UJ, Obe G, Friesen M, et al. Role of lime in the generation of reactive oxygen species from betel-quid ingredients. Environ Health Perspect 1992;98:203-205.
38. Hecht SS, Carmella SG, Edmonds A, et al. Exposure to nicotine and a tobacco-specific carcinogen with duration of use of smokeless tobacco. Tob Control 2008;17:128-131.
39. Mirvish SS. Formation of N-nitroso compounds: chemistry, kinetics, and in vivo occurrence. Toxicol Appl Pharmacol 1975;31:325-351.
40. Nair J, Ohshima H, Nair UJ, et al. Endogenous formation of nitrosamines and oxidative DNA-damaging agents in tobacco users. Crit Review Toxicol 1996;26:149-161.